The next two decades of mifepristone at FDA: History as destiny

Congressional and presidential records reveal a consistent pattern of political intercession with the regulatory authority of the Food and Drug Administration (FDA) over the approval and labeling of mifepristone (RU-486). This pattern is unlikely to abate any time soon. It is against this backdrop that we examine herein the ongoing legislative and legal disputes over mifepristone at a point in time which is just beyond the 20th anniversary of its approval by the FDA for the medical termination of intrauterine pregnancy. (c) 2022 Elsevier Inc. All rights reserved.

Automated summary

Congressional and presidential records indicate a consistent pattern of political interference with the FDA's regulatory authority over mifepristone. This article examines the ongoing legislative and legal disputes surrounding mifepristone, which comes just after its 20th anniversary of FDA approval for medical termination of intrauterine pregnancy.